Connect with us

Micro Caps

PCT Ltd (OTCMKTS: PCTL) Powerful Reversal Forming as Hydrolyte Gains Traction and Investors Await Coming Release on Two New Subsidiaries & JVs

Published

on

PCT Ltd (OTCMKTS: PCTL) is making a powerhouse move up the charts after reversing off support levels just over the $0.01 mark. The stock has a long history of highly explosive moves skyrocketing from triple zeroes to highs of a dime in early 2020, a historic run that Microcapdaily reported on back in the day. Currently PCTL is under heavy accumulation on a massive surge of volume and has a significant gap to fill from current levels with investors looking at current price levels as significantly oversold. PCTL is quickly emerging as an investor favorite and is currently among the most actively searched and talked about stocks in small caps. The stock is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to multi-dollars – a break over $0.025-$0.03 level marks the first leg up, a break over $0.10 and its blue skies ahead for PCTL. 

PCTL reversal gained traction after the Company announced on twitter it will release more information on the two new subsidiaries and the JVs next week. The Company will explain this massive 0&G opportunity and their plan to effectively monetize fluid sales to the industry. In the face of coronavirusd PCTL’s Hydrolyte has been quickly gaining traction as witnessed by their growing revenus; last year the Company executed a domestic supply agreement with Maverick Energy Services and Maverick Environmental Solutions of Holdenville, Oklahoma for a minimum of 1,000,000 gallons of PCT Hydrolyte® to be delivered over the next twelve months. An initial order has been fulfilled on this contract. PCTL boasts fast growing revenues; Last month the Company reported Q1 results; Revenues for three months ended March 31, 2021, were $395,519, an increase of 45% from $272,812 in the same period of 2020. Also, recently the Company reported it has settled all outstanding warrants. 

PCT Ltd (OTCMKTS: PCTL) operating out of their offices on Commerce Street, in Little River, South Carolina is focused on acquiring, developing, and providing sustainable, environmentally responsible disinfecting, cleaning and tracking technologies. The Company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K. PCTL is fully reporting OTC and has been “pink current” since April of this year. 

PCT launched its patented Annihilyzer® Infection control system, a revolutionary product line that reduces the likelihood of acquiring Hospital Associated Infections within hospitals in the United States and Europe. PCT’s Annihilyzer® System has now been deployed in about a dozen hospitals with some of the hospitals moving on to to multiple systems. Management said it expects to grow at the rate of a minimum of two hospitals a month for the first part of this year and then to double that for the second half of the year. PCTL’s area of expertise is in preventing spread of infectious diseases by applying Hydrolyte (HOCl) to surfaces. PCTL’s Hydrolyte hasn’t been tested against variant forms of coronaviruses however it is anticipated the Company’s products used to clean & disinfect will be highly effective against variant forms of coronaviruses. 

In the face of coronavirus PCTL’s Hydrolyte has been quickly gaining traction as witnessed by their growing revenues; last year the Company executed a domestic supply agreement with Maverick Energy Services and Maverick Environmental Solutions of Holdenville, Oklahoma for a minimum of 1,000,000 gallons of PCT Hydrolyte® to be delivered over the next twelve months. An initial order has been fulfilled on this contract. 

PCTL’s Hydrolyte meets the requirement of the FDA and USDA, to be a non-rinse sanitizing agent. In the world of dealing with food, why not use a product that actually kills food-borne pathogens – without containing any toxic chemicals that would harm the quality of the product? Forget harsh, toxic chemicals. Our process only requires salt, water and electricity to produce two products –a chlorine-based antimicrobial agent and an excellent degreasing cleaner. Hydrolyte produces an effective variable PPM hypochlorous acid solution that is created through an electrolytic process called Electro-Chemical Activation (ECA). It occurs by temporarily modifying the properties of water, by passing weak salt brine through an electrolytic cell and temporarily changing the properties of the salt water into a powerful oxidizing agent exhibiting highly effective antimicrobial properties.  

To Find out the inside Scoop on PCTL subscribe to Microcapdaily.com Right Now by entering your Email in the box below
PCTL

Last month the Company reported Q1 results; Revenues for three months ended March 31, 2021, were $395,519, an increase of 45% from $272,812 in the same period of 2020. The company recently installed its newest generation of the Annihilyzer® Infection Control equipment in a North Carolina hospital. Since that installation, management has assessed the new generator’s design and productivity in a real-world environment, and it has exceeded internal expectations for reliability and consistency. 

Gary Grieco, PCTL’s Chairman and Chief Executive Officer stated, “Our strategy, as we entered into 2021, was to establish a distribution network that allowed us an opportunity to capitalize on the ongoing efforts and to ensure the availability of Hydrolyte®, a highly effective, US EPA registered hospital disinfectant. We will continue to offer resources and support to our distributors and other ‘partners’ to move the leasing and/or sale of equipment, sale of fluids, and revenues from licensing, higher. As with all improved ideas, quality assurance is first assessed in the shop, but the final determination comes from within a functioning customer venue. We are encouraged with the performance of our newest Annihilyzer equipment and believe it can be a true leader in producing HOCl-based disinfectant and cleaner for all types of environments and surfaces. We also believe our distributors, clients, and customers, will all be impressed with the new equipment’s capabilities. Currently we have three more of our newest models being assessed during the rigorous quality assurance process we put them through, and we are building more of our newest generation of Annihilyzer Infection Control Systems in order to fulfill the orders that are in our sales pipeline.” 

For More on PCTL Subscribe Right Now!

PCTL s making a powerhouse move up the charts after reversing off support levels just over the $0.01 mark. The stock has a long history of highly explosive moves skyrocketing from triple zeroes to highs of a dime in early 2020, a historic run that Microcapdaily reported on back in the day. Currently PCTL is under heavy accumulation on a massive surge of volume and has a significant gap to fill from current levels with investors looking at current price levels as significantly oversold. PCTL is quickly emerging as an investor favorite and is currently among the most actively searched and talked about stocks in small caps. The stock is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to multi-dollars – a break over $0.025-$0.03 level marks the first leg up, a break over $0.10 and its blue skies ahead for PCTL. PCTL reversal gained traction after the Company announced on twitter it will release more information on the two new subsidiaries and the JVs next week. The Company will explain this massive 0&G opportunity and their plan to effectively monetize fluid sales to the industry. In the face of coronavirusd PCTL’s Hydrolyte has been quickly gaining traction as witnessed by their growing revenus; last year the Company executed a domestic supply agreement with Maverick Energy Services and Maverick Environmental Solutions of Holdenville, Oklahoma for a minimum of 1,000,000 gallons of PCT Hydrolyte® to be delivered over the next twelve months. An initial order has been fulfilled on this contract. PCTL boasts fast growing revenues; Last month the Company reported Q1 results; Revenues for three months ended March 31, 2021, were $395,519, an increase of 45% from $272,812 in the same period of 2020. Also, recently the Company reported it has settled all outstanding warrants. We will be updating on PCTL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PTCL.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PCTL either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19

Published

on

On the cusp of a cure for COVID, one of the most promising yet under-the-radar biotech stocks on the OTC is generating much well-deserved buzz in the scientific community and is poised to go viral.

Bioxytran Inc. (OTCMKTS: BIXT) over the weekend had their phase 2 top-line results published in the peer-reviewed journal “Vaccines.” There is a not-so-subtle tinge of irony in that name because while their drug is nothing like a vaccine, there is no doubt about its efficacy– 100% PCR negative rate by day 7 versus 6% in placebo.  The medical journal article was titled “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial.” This is a landmark journal article because – until now – only one other drug, Harvoni, had equaled a 100% responders rate in the past decade.  Harvoni ultimately ended up being a cure for Hepatitis C Virus.

At this point in Bioxytran’s drug development pipeline, it essentially has a functional cure for COVID-19 that simply needs a pivotal phase 3 trial to show the true extent of their discovery.  Their drug is a galectin antagonist, which neutralizes the now infamous spike proteins by placing a carbohydrate sheath over the spikes making attachment to the cell impossible. The carbohydrates binding grip is so tight on the virus that it carries it around in the blood until it is eventually filtered out by the liver and excreted. 

If solving the pandemic wasn’t enough, the company recently reported that in vitro studies suggest the drug would be effective in Influenza and RSV.  Yet despite the fact that this one drug could seemingly end upper respiratory infections, which most of us refer to as a “common cold,” it has a nominal market cap of just $50 million.       

For the past three months, BIXT has been teasing this peer-reviewed article as a catalyst and a major value inflection point for the company. Despite that, investors haven’t gotten the hint, and have been steadily selling into this inflection point. Even though the company has yet to report it in a press release, the scientific community is understandably going crazy over it. Investors, however, are seemingly oblivious to the viral traffic and simply not paying attention to the sheer magnitude of the discovery–a functional cure for COVID and the methodology to seemingly combat any virus.  

One of the reasons peer review is so important for a biotech is that major media outlets won’t touch the science without it. With its publication, this article means that BIXT now has an opportunity to tell its story on network media. The biggest risk that investors now face in BIXT is FOMO, driven by an unexpected media appearance that ushers unbridled buying into the name and leaves tepid investors chasing up.   

If the article itself wasn’t enough, their peer-reviewed article was picked up by a major biotech influencer on Twitter, quickly garnering more than 100k hits.  The influencer, Chris Turnbull, summarized the article highlighting key points like the rapid viral clearance in 3 days through entry inhibition and suggested the ideal use is when you know you were exposed. He hammered the point that ProLectin-M was for standard-risk patients and that Paxlovid was for high-risk groups with at least one medical condition.   

This discovery changes the COVID landscape permanently.  Multi-billion dollar antiviral drugs like Paxlovid and Lagevrio can’t hold a candle to the viral clearing power of BIXT’s galectin antagonist. Looking at the Twitter account of BIXT Chief Commercial Officer Michael Sheikh, it’s clear that there are some ongoing discussions with big pharma that have not yielded any fruit. But big pharma may not be their only option. BIXT has also said they are looking to partner with companies with large cash balance sheets.  Both galectin antagonist companies Galectin Therapeutics (NASDAQ: GALT) and Galecto Bioscience (NASDAQ: GLTO) fit the profile and are the subject of a number of relatively supportive tweets by Sheikh.  Sleuthing Sheikh’s LinkedIn profile reveals hardcore evidence of that sort of dealmaking with clusters of top executives in certain companies and networking, which suggests significant activity among their larger Galectin-focused peers.  In an emerging growth interview, the CCO did say that he got a lot of business cards and was networking.      

There exists a huge chasm between the current market cap and what it ought to be given that it successfully completed a phase 2 and nailed the endpoint with a perfect score. The CCO described in an Emerging Growth video how valuations work and a number of comparables in the $500 million range for a number of disease indications that BIXT is developing.  The stock has a very tiny float of 19 million with an OS of 123 million.  This represents a float of 15% and insiders own over 60%.  There is no dilution from the convertible notes as they have company-friendly terms that allow up to 5% conversion into restricted common stock. In an Emerging Growth interview a couple of months ago, the CCO acknowledged the stock’s current challenge, indicating a legacy seller was responsible for half the daily volume and was almost gone. In early March after a ZeroHedge article was published, the stock went on a record run to $1.05 in a matter of minutes before short forces brought it back down. On March 7th it looks like the seller ran out of inventory for the day and the demand just lifted the stock price allowing it to go through a short period of natural price discovery.  The long-term legacy seller seems to be at the end of his block, which means any news announcement could push the stock higher.    

Low-Risk Explosive Reward Profile

There is no doubt that BIXT has incredible potential yet the stock continues to languish. With the anemic volume, it’s very difficult to diagnose what the root cause is for the disconnect from the comparable valuations established by big pharma in the $500 million region and BIXT’s current $50M cap. If one article that generated a little bit of buying pushed it to the brink of explosiveness, perhaps there is more stock from this legacy seller that is still controlling the narrative.  

Upcoming Catalysts

For the investor with a longer-term view, BIXT represents a safe place to park funds for explosive returns.  The upcoming catalysts are a dosing of patients in India for the dose optimization trial, a potential IND from the FDA, and of course, the announcement of the peer-reviewed journal article.  While it’s uncertain which catalyst will send the stock into overdrive it’s abundantly clear this is one of the most undervalued stocks in OTC.   

Pound-for-Pound Comparison of Paxlovid and PLM

Paxlovid also helped lower the length of time people with underlying medical conditions were infectious.  However, Paxlovid is not a very effective drug and is walking a tightrope with respect to its approval as more and more real-world data reveals their toxicity.  

Here is a chart capture from the company’s latest scientific webinar that shows a side-by-side comparison for illustrative purposes.  The charts show that Paxlovid can barely turn 30% of the patients PCR negative by day 20 whereas a majority of the PLM patients were PCR negative on day 3.  This is an absolute game-changer in controlling the pandemic.  The other thing that this peer-reviewed journal highlighted is that the symptoms were eliminated and without those symptoms, people were unlikely to develop Long COVID.  It’s very reasonable to believe that PLM stops Long COVID due to its mechanism of action as well as the fact that it appeared to eliminate symptoms in this trial, as seen in the picture below.  While it’s nice that Paxlovid stops hospitalization and death, PLM takes it to a new level by making you feel better faster and eliminating the risk of Long COVID.

Investment Summary

Bioxytran is not only sitting on a solution for COVID and a possible end to the pandemic, but it appears they can also treat Long COVID and a number of viruses.  All this information is out there in the public domain and investors seem to be sitting on their hands waiting for something more to happen.  It’s unclear what that trigger will be.  Will it be a video interview on major media? Will it be the IND announcement from the FDA? Or will it be an explosion of XBB1.16 cases in India whereby they fast-track the PLM development in the country?  Whatever the catalyst, the risk/ reward scenario on BIXT is one of the best in all of the OTC.  The small float coupled with the lack of an S-1 on file eliminating the risk of immediate dilution bodes well for either a long-term or medium-term investor.  

Investors need to ask themselves if they could have invested in penicillin knowing the impact it was going to have last century would they have dived in?  Investors are facing a similar scenario with PLM.  This is perhaps the biggest antiviral discovery of the century which amounts to a functional cure for COVID and possibly other viruses.  Will investors stay on the sideline because some grumpy shareholder is selling not allowing immediate price discovery or will they step up to secure their place in history?  Time will tell, but what is certain is that PLM will save an immeasurable amount of lives and take away untold suffering if it can navigate its way to regulatory approval. But while BIXT may be curing Covid, there is still only one cure for FOMO. Investors would do well to stop waiting on the sidelines to enter or affirm their positions before this game-changing anti-viral goes viral.     

Disclosure: MicroCap Daily and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.     

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.